AIMS: Two single-nucleotide polymorphisms (SNPs) at the calcium-sensing receptor (CASR) gene were previously associated with kidney stones in patients with primary hyperparathyroidism (PHPT): rs1501899, likely associated with a decrease in CASR expression, and Arg990Gly, causing a gain of CASR function. To evaluate the interaction of these two SNPs in the stone risk, we tested the association of stones with the genotype at both SNPs in PHPT patients and the association of rs1501899 with CASR expression as messenger RNA (mRNA) in human kidney samples. METHODS AND RESULTS: Two hundred and ninety-six PHPT patients were genotyped at the rs1501899 and Arg990Gly SNPs. Minor allele frequency at tested SNPs was higher in PHPT stone formers relative to non-stone forming patients. PHPT patients carrying one or two copies of the minor allele at both rs1501899 and Arg990Gly (n = 16) had the maximal risk of stones (odds ratio, OR 8.3) and higher serum ionized calcium compared with homozygous patients for the wild-type allele at both SNPs. CASR expression as mRNA was measured by real time polymerase chain reaction (PCR) in normal kidney medulla samples from 109 subjects. CASR mRNA was significantly lower in medulla samples from homozygotes for the minor allele at rs1501899 than in subjects with other genotypes. CONCLUSIONS: We conclude that the simultaneous presence of the minor allele at rs1501899 and Arg990Gly may amplify the kidney stone risk in PHPT patients, despite their apparently opposite effects on CASR function in the kidney.
AIMS: Two single-nucleotide polymorphisms (SNPs) at the calcium-sensing receptor (CASR) gene were previously associated with kidney stones in patients with primary hyperparathyroidism (PHPT): rs1501899, likely associated with a decrease in CASR expression, and Arg990Gly, causing a gain of CASR function. To evaluate the interaction of these two SNPs in the stone risk, we tested the association of stones with the genotype at both SNPs in PHPT patients and the association of rs1501899 with CASR expression as messenger RNA (mRNA) in human kidney samples. METHODS AND RESULTS: Two hundred and ninety-six PHPT patients were genotyped at the rs1501899 and Arg990Gly SNPs. Minor allele frequency at tested SNPs was higher in PHPT stone formers relative to non-stone forming patients. PHPT patients carrying one or two copies of the minor allele at both rs1501899 and Arg990Gly (n = 16) had the maximal risk of stones (odds ratio, OR 8.3) and higher serum ionizedcalcium compared with homozygous patients for the wild-type allele at both SNPs. CASR expression as mRNA was measured by real time polymerase chain reaction (PCR) in normal kidney medulla samples from 109 subjects. CASR mRNA was significantly lower in medulla samples from homozygotes for the minor allele at rs1501899 than in subjects with other genotypes. CONCLUSIONS: We conclude that the simultaneous presence of the minor allele at rs1501899 and Arg990Gly may amplify the kidney stone risk in PHPT patients, despite their apparently opposite effects on CASR function in the kidney.
Authors: Conall M O'Seaghdha; Qiong Yang; Nicole L Glazer; Tennille S Leak; Abbas Dehghan; Albert V Smith; W H Linda Kao; Kurt Lohman; Shih-Jen Hwang; Andrew D Johnson; Albert Hofman; Andre G Uitterlinden; Yii-Der Ida Chen; Edward M Brown; David S Siscovick; Tamara B Harris; Bruce M Psaty; Josef Coresh; Vilmundur Gudnason; Jacqueline C Witteman; Yong Mei Liu; Bryan R Kestenbaum; Caroline S Fox; Anna Köttgen Journal: Hum Mol Genet Date: 2010-08-12 Impact factor: 6.150
Authors: Giuseppe Vezzoli; Alfredo Scillitani; Sabrina Corbetta; Annalisa Terranegra; Elena Dogliotti; Vito Guarnieri; Teresa Arcidiacono; Vera Paloschi; Francesco Rainone; Cristina Eller-Vainicher; Loris Borghi; Antonio Nouvenne; Angela Guerra; Tiziana Meschi; Franca Allegri; Daniele Cusi; Anna Spada; David E C Cole; Geoffrey N Hendy; Donatella Spotti; Laura Soldati Journal: Eur J Endocrinol Date: 2010-12-23 Impact factor: 6.664
Authors: Annalisa Terranegra; Anita Ferraretto; Elena Dogliotti; Milena Scarpellini; Sabrina Corbetta; Anna Maria Barbieri; Anna Spada; Teresa Arcidiacono; Francesco Rainone; Andrea Aloia; Daniele Cusi; Giuseppe Vezzoli; Laura Soldati Journal: J Mol Endocrinol Date: 2010-08-03 Impact factor: 5.098
Authors: G Vezzoli; A Terranegra; T Arcidiacono; R Biasion; D Coviello; M L Syren; V Paloschi; S Giannini; G Mignogna; A Rubinacci; A Ferraretto; D Cusi; G Bianchi; L Soldati Journal: Kidney Int Date: 2007-02-28 Impact factor: 10.612
Authors: Andrew E Evan; James E Lingeman; Fredric L Coe; Nicole L Miller; Sharon B Bledsoe; Andre J Sommer; James C Williams; Youzhi Shao; Elaine M Worcester Journal: Kidney Int Date: 2008-04-30 Impact factor: 10.612
Authors: Melita M Dvorak; Tsui-Hua Chen; Benjamin Orwoll; Caitlin Garvey; Wenhan Chang; Daniel D Bikle; Dolores M Shoback Journal: Endocrinology Date: 2007-04-05 Impact factor: 4.736
Authors: Maria M Litvinova; Kamil Khafizov; Vitaly I Korchagin; Anna S Speranskaya; Aliy Yu Asanov; Alina D Matsvay; Daniil A Kiselev; Diana V Svetlichnaya; Sevda Z Nuralieva; Alexey A Moskalev; Tamara V Filippova Journal: Front Genet Date: 2021-05-12 Impact factor: 4.599